Clinical trials: Chemotherapy-induced Nausea and Vomiting (CINV)
Chemotherapy-induced Nausea and Vomiting (CINV)
Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents
At present, the clinical studies of 5-HT3RA are aimed at nausea and vomiting induced by single-day chemotherapy, but there are many chemotherapy schemes that require multi-day administration in clinical practice.
- Trial name
- NCT04472143
- Testing
- Granisetron Transdermal Delivery System
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Nausea, Vomiting
Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)
The management of chemotherapy-induced nausea and vomiting (CINV) has evolved in recent years and became less frequent. CINV include early (occurring within 24 hours of chemotherapy administration) and delayed (occurring within 4…
- Trial name
- NVCI (NCT02767791)
- Testing
- Acupuncture, Auriculotherapy
- Where
- 5 sites in France
- Volunteers
- 116 people
- Sponsor
- Hopital Foch
Nausea and Vomiting, Chemotherapy-Induced
Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting
This is a multicenter, randomized, double-blind, active-controlled dose-finding study. About 180 subjects who receive a high emetic chemotherapy are planned to be enrolled and randomized into three groups by a ratio of 1:1:1.
- Trial name
- CINV (NCT06593782)
- Testing
- HSK21542, Dolasetron
- Volunteers
- 180 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Chemotherapy-induced Nausea and Vomiting (CINV)
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
This study is Phase 2 pharmacokinetic (PK) and pharmacodynamic (PD) dose-finding study of oral netupitant administered concomitantly with oral palonosetron in pediatric cancer patients for the prevention of nausea and vomiting…
- Trial name
- CINV (NCT03204279)
- Testing
- Netupitant, Palonosetron
- Where
- 17 sites in United States, Russia and 2 more
- Volunteers
- 67 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-Induced Nausea and Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
The study will test aprepitant for the prevention of CINV in patients receiving their initial cycle of Moderately Emetogenic Chemotherapy (MEC).
- Trial name
- NCT00337727
- Testing
- aprepitant, Comparator: ondansetron, Comparator: dexamethasone
- Volunteers
- 848 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV)…
- Trial name
- NCT00787566
- Testing
- Intranasal granisetron
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
Nausea, Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
A multicenter trial to assess the safety and efficacy of an investigational drug in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed solid tumors who will be treated with a chemotherapy…
- Trial name
- NCT00090207
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 4 days
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC
This prospective, multicenter, non-comparative, open-label trial design aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by…
- Trial name
- NCT07482891
- Testing
- Fosrolapitant and Palonosetron Hydrochloride for Injection, Dexamethasone, Olanzapine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai 6th People's Hospital
Chemotherapy-Induced Nausea and Vomiting (CINV)
Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting
The primary objective of this clinical study is to evaluate the efficacy and safety of nanocrystalline megestrol acetate combined with a 5-HT3 receptor antagonist for the prophylaxis of nausea and vomiting caused by moderately…
- Trial name
- NCT07246070
- Testing
- nanocrystalline megestrol acetate combined with ondansetron, dexamethasone combined with ondansetron
- Volunteers
- 127 people
- Sponsor
- AIPING ZHOU
Breast Cancer
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
This is a prospective, multicenter, open label, non-comparative trial in Spain. The primary objective of this study is to determine the complete response, defined as no vomiting and no use of rescue treatment, in women with…
- Trial name
- NCT01298193
- Testing
- Aprepitant
- Where
- 13 sites in Spain
- Volunteers
- 212 people
- Sponsor
- Spanish Breast Cancer Research Group
Chemotherapy-induced Nausea and Vomiting
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant dimeglumine (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic…
- Trial name
- NCT04054193
- Testing
- Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
- Where
- 26 sites in United States, Greece and 7 more
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
- Trial name
- NCT01596400
- Testing
- granisetron transdermal system, Granisetron IV
- Where
- 12 sites in United States
- Volunteers
- 19 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chemotherapy-induced Nausea and Vomiting (CINV)
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.
- Trial name
- NCT00952341
- Testing
- aprepitant, dexamethasone, granisetron
- Volunteers
- 421 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Cancer, Liver Metastasis
Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin
Objectives: This protocol is part of a larger grant funded by the NCI to create an international research center to study Traditional Chinese Medicine (TCM).
- Trial name
- NCT00430313
- Testing
- Electro-Stimulation of Yongquan (K1) Acupoint
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapy-Induced Nausea and Vomiting (CINV), Hematopoietic Stem Cell Transplantation (HSCT)
Acupuncture to Prevent Nausea and Vomiting After Stem Cell Transplant
This study is testing whether acupuncture at a point on the wrist called "Neiguan" can help reduce nausea and vomiting in patients undergoing stem cell transplantation.
- Trial name
- NCT07747194
- Testing
- Acupuncture, Conventional care
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xiao Wang
Chemotherapy-Induced Nausea and Vomiting (CINV), Nausea
HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World Study
HR20013 is a newly approved medicine in China to prevent nausea and vomiting from anticancer treatment. This prospective, observational, multicenter real-world study will enroll about 3,000 patients receiving this medicine as…
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV), Nausea, Vomiting, Neoplasms
- Trial name
- HR20013-RWS (NCT07874308)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Sun Yat-sen University
Chemotherapy-induced Nausea and Vomiting
Auricular Acupressure for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most common and distressing adverse effects in patients receiving highly emetogenic chemotherapy (HEC).
- Trial name
- AACINV (NCT07760766)
- Testing
- Auricular Acupressure
- Where
- China
- Volunteers
- 332 people
- Sponsor
- China Medical University, China
Chemotherapy-induced Nausea and Vomiting
The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy
This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced delayed nausea and vomiting (CINV) in…
- Trial name
- NCT03601871
- Testing
- Thalidomide, Dexamethasone, 5-HT3 antagonists
- Where
- 29 sites in China
- Volunteers
- 880 people
- Sponsor
- Yunpeng Liu
Nausea, Vomiting
Laser Acupuncture Against Nausea in Children
To investigate whether nonthermal low level laser acupuncture has beneficial effects on nausea and vomiting in children receiving highly emetogenic chemotherapy for a malignant solid tumor.
- Conditions
- Nausea, Vomiting, Cancer
- Trial name
- NCT00528554
- Testing
- laser acupuncture
- Where
- 2 sites in Germany
- Volunteers
- 25 people
- Sponsor
- University Children Hospital Homburg
Chemotherapy-induced Nausea and Vomiting (CINV)
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
Transdermal granisetron has been shown to as effective as oral/ intravenous granisetron when administered with or without dexamethasone.
- Trial name
- NCT04912271
- Testing
- Granisetron transdermal patch, Palonosetron, Aprepitant
- Volunteers
- 140 people
- Sponsor
- Fudan University